Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.02
$0.00
▼
$0.11
$16K-0.4430,352 shs3,004 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+6.7%		$0.00
$0.00
▼
$0.02
$100K1.87114,177 shs271,578 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.03
$0.00
▼
$6.79
$44K-1.761,989 shs2 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.03
$0.01
$0.00
▼
$0.06
$135K1.464,642 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+50.00%-40.00%+200.00%-99.30%-99.55%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-11.76%-16.67%-51.61%-28.57%-86.84%
Shineco stock logo
SISI
Shineco
0.00%0.00%+52,400.00%+4,900.00%-91.25%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+71.33%+71.33%+102.36%-49.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.02
$0.00
▼
$0.11
$16K-0.4430,352 shs3,004 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+6.7%		$0.00
$0.00
▼
$0.02
$100K1.87114,177 shs271,578 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.03
$0.00
▼
$6.79
$44K-1.761,989 shs2 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.03
$0.01
$0.00
▼
$0.06
$135K1.464,642 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+50.00%-40.00%+200.00%-99.30%-99.55%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-11.76%-16.67%-51.61%-28.57%-86.84%
Shineco stock logo
SISI
Shineco
0.00%0.00%+52,400.00%+4,900.00%-91.25%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+71.33%+71.33%+102.36%-49.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A
Shineco stock logo
SISI
Shineco
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.02N/AN/A$4.04 per share0.00
Shineco stock logo
SISI
Shineco
$9.60M0.00N/AN/A$4,679.15 per share0.00
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$0.36N/AN/AN/AN/A-78.22%-23.50%12/2/2026 (Estimated)
Shineco stock logo
SISI
Shineco
-$22.45M-$204.00N/AN/AN/A-380.55%-79.89%-33.01%N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%11/10/2026 (Estimated)

Latest BPTH, PTPI, VINC, and SISI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$8.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
Shineco stock logo
SISI
Shineco
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74
Shineco stock logo
SISI
Shineco
N/A
0.72
0.71
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
Shineco stock logo
SISI
Shineco
4.08%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
Shineco stock logo
SISI
Shineco
0.02%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable
Shineco stock logo
SISI
Shineco
119415,000415,000Not Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
January 18, 2026  |  defenseworld.netD
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times
July 9, 2025  |  manilatimes.netM
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111291/0/en/Vincerx-Pharma-Inc-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal-and-Announces-Potential-Range-for-Distributions-to-Stockholders.html
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
July 2, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VINC/press-releases/
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101905/0/en/Vincerx-Pharma-Inc-Announces-Adjournment-of-Special-Meeting-Will-Reconvene-Meeting-on-July-16-2025-to-Secure-Votes-Needed-to-Approve-Dissolution-Proposal.html
Vincerx Pharma announces plan to delist from Nasdaq
April 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-plan-to-delist-from-nasdaq-1034597516
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vincerx-pharma-inc-announces-intent-204500865.html
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/17/3063864/0/en/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-deregister-with-the-sec.html
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down
April 9, 2025  |  fiercebiotech.comF
Vincerx terminates letter of intent with Global Digital, initiates wind down
April 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-terminates-letter-of-intent-with-global-digital-initiates-wind-down-1034562524
Financially struggling drugmaker's potential rescue falls apart. It now will wind down
April 9, 2025  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2025/04/08/cancer-vincerx-pharma-qumulusai-merger-fails.html
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
April 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/08/3057992/0/en/Vincerx-Pharma-Announces-Termination-of-Letter-of-Intent-and-Board-Authorization-to-Pursue-Wind-Down-Activities.html
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-non-binding-loi-for-qumulus-ai-combination-1034489795
Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
March 18, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64858522-vincerx-pharma-inc-vincerx-pharma-announces-non-binding-letter-of-intent-for-business-combination-with-qumulusai-399.htm
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis
March 18, 2025  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 0.00 (0.00%)
As of 10/12/2026 09:30 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0032 +0.00 (+6.67%)
As of 02:30 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Shineco stock logo

Shineco NASDAQ:SISI

$0.10 0.00 (0.00%)
As of 10/12/2026

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.03 0.00 (0.00%)
As of 10/12/2026

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas